As Paul noted in his recent post, we’ve asked outsiders to review our portfolio of grants and tell us (1) their assessment of what we’ve been doing and (2) some ideas of opportunities that we should be pursuing.
Today we’ll summarize their comments about our work so far; over the next few days we’ll also present the opportunities they suggest for Pioneer. As Paul has said, please let us know what you think.
For example, Martin Seligman, Fox Leadership Professor of Psychology at the University of Pennsylvania, tells us:
I am impressed with your taste in projects. Of the ten leading grants, a couple of breakthroughs (e.g. much better use of health records) seemed possible. While some grants are high payoff-low probability grants, none struck me as sure losers. And I like your reliance on entrepreneurial activity both in the market place and among academics. The latter group, so reliant on relatively dull next steps, needs goading toward more imaginative project, particularly in the area of health and disease.
While Lewis Sandy, MD, Senior Vice President, Clinical Advancement at UnitedHealth Group (and former RWJF VP), observes:
The current Pioneer portfolio appears to be serving two functions: First it appears to serve as mechanism to fund relatively conventional programs in areas not traditionally funded by RWJF. This may serve as “R &D” for the main foci of RWJF grant making and/or serve to support areas of interest to RWJF constituents and staff. Second, it appears to be serving as a means to invest in “experiments” in particular domains in health/healthcare and/or in novel approaches to changes.
Overall, while the Portfolio has a wider range of grantees, problem areas, and projects than is typical fro RWJF, it is fairly conservative for a “high risk” portfolio. In particular, the Portfolio overly emphasizes an analytic, fact driven approach to change (what is and how to get there), rather than alternatives, such as social, emotional or artistic approaches (what might be).
Wylie Burke, M.D., Chair, Department of Medical History and Ethics, and Professor of Medical History and Ethics, University of Washington School of Medicine, points out that:
The portfolio of past and present projects seems robust and usefully diverse, particularly taking into account how recently this initiative was founded. The currently funded projects seem to break down into about half that are potentially breakthroughs and half that provide an opportunity for incremental change. This seems like a good balance. I found some projects difficult to characterize by this rubric: for example, where to put a project to design a new healthcare garment for patients. It’s a great idea whether it is characterized as breakthrough or incremental.
And finally, Alice Gosfield, a health lawyer and Chairman of the Board of PROMETHEUS Payment, Inc. (a not-for-profit national multi-stakeholder project to develop a new provider payment model), warns:
I find the vast majority of the projects [in the Pioneer Portfolio] to be incremental. I don’t see much contrarian thinking or really radical propositions that generate – “yikes, that’s scary!” or “How in the world will they do that?” which is what creates real breakthroughs. Some of it is just minor testing of minor innovations. The projects, which I think offer real potential breakthroughs—the possibility for contributing to a truly, radically different reality, even if only in small ways, are the medical courts, video and computer gaming for messaging, creating new financial markets for social entrepreneurs, creating a medical research investment analysis service and the RWJF X Prize. The latter three also have the quality of potential seeding of yet additional breakthroughs. You may want to add a grant criterion: How will what you are asking us to support not be replicable itself but stimulate further breakthroughs?
Agree? Disagree? Other observations?